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as models for future in vivo studies on the role of MrgX2 in human disease conditions.
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ABSTRACT
Background: Mast cells (MCs) are granule containing immune cells with varied
functions in both health and disease. Mas-related gene X2 (MrgX2) expressed on
human but not mouse MCs functions as a binding site for a wide variety of
biologically relevant cationic peptides including human beta defensins (hBDs),
LL-37, eosinophil-derived major basic protein (MBP) and substance P (SP)
leading to degranulation. Atopic dermatitis is a cutaneous inflammatory disease
that involves MCs, eosinophils and the neuropeptide SP. Rosacea is a chronic
inflammatory cutaneous disease, which involves dysregulation of LL-37 and MCs
and is associated with neurogenic inflammation mediated by neuropeptides such
as SP. MCs, hBDs and LL-37 are involved in the pathogenesis of chronic
periodontitis. Increased numbers of MCs are present in the bronchial smooth
muscles of patients with asthma. Furthermore, neutrophils and eosinophils play
important roles in the last phase of allergic asthma. However, possible roles of
MrgX2 on host defense and inflammatory diseases have not been determined.

Objectives: We sought to determine if human skin, gingiva and lung MCs
express MrgX2 and to test if its expression is upregulated in atopic dermatitis,
rosacea, chronic periodontitis and asthma. We investigated the localization of
MrgX2 before and after stimulation with a known ligand cortistatin and finally we
tested the feasibility of utilizing humanized mice as a model for in vivo functional
studies on MrgX2.

Methods: We analyzed skin samples from 3 patients with atopic dermatitis, 2
patients with rosacea and 3 control subjects. For the study on chronic
periodontitis, we analyzed gingiva tissue from 3 patients with chronic periodontitis
and 1 control subject. Lung tissue samples from 6 patients who died of asthma
related complications and 6 control subjects that died of other causes as well as
humanized mice lung tissue were also analyzed. Immunohistochemical analysis
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was used to determine the presence of MCs in relation to structural cells in the
tissues. Immunofluorescence double-staining method was used to detect the
expression of MrgX2 by MCs. RBL-2H3 cells transiently expressing MrgX2 were
used to investigate receptor localization.

Results: MCs in healthy and diseased skin, gingiva and lungs express MrgX2.
The expression of MrgX2 was not significantly different in the skin of patients
diagnosed with atopic dermatitis and rosacea compared with control subjects.
We did not quantitate the expression of MrgX2 in chronic periodontitis due to
limited sample size, however MCs in gingiva of chronic periodontitis patients
express MrgX2. There was a significant increase in MCs, MrgX2-positive cells as
well as MrgX2-positive MCs in asthmatic lung tissue compared with healthy lung
tissue. Using RBL-2H3 cells, we found that MrgX2 was expressed on the plasma
membrane as well as intracellularly and on stimulation, we found evidence of
possible mobilization of the receptor. Finally, we found that human MCs, which
develop in the lungs of humanized mice, express MrgX2.

Conclusions: Expression of MrgX2 by MCs in healthy skin, gingiva and lung
suggests that it plays an important role in host defense by enabling crosstalk
between MCs, hBDs expressed by epithelial cells and LL-37 expressed by
neutrophils. Our finding that MCs that express MrgX2 are upregulated in chronic
asthma suggests it participates in the pathogenesis of asthma. Given that hBD3,
LL-37 and eosinophil-derived peptides are increased in periodontits, rosacea and
AD, respectively suggest that MrgX2 contributes to these diseases via increased
MC degranulation. Finally, humanized mice may be used as models for future in
vivo studies on the role of MrgX2 in human disease conditions.
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1. INTRODUCTION
1.1

Mast cells

1.1.1. Biology of Mast cells
Mast cells (MCs) are multifunctional immune cells that are derived from
hematopoietic stem cells (HSCs) in the bone marrow but differentiate locally in
the tissues (1, 2). MCs are present in almost all vascularized tissue, being more
abundant at sites that are exposed to external pathogens and allergens such as
the skin and the mucosal surfaces of the gastro-intestinal and respiratory tracts
(3, 4). They are usually found under the epithelium residing in the connective
tissue adjacent to blood vessels and in close proximity to nerve fibers (4-8). The
growth, development and maturation of MCs are regulated by the c-kit ligand,
stem cell factor (SCF) as well as other factors including nerve growth factor,
neurotrophin-3, IL-3 and the Th2 associated cytokines IL-4 and IL-9 (9, 10).

Human MCs are classified into two subtypes based on the composition of their
secretory granules. Thus, MCT, predominantly express tryptase while MCTC
express both tryptase and chymase (11). MCTC are more prominent in skin and
intestinal submucosa while MCT are more prominent in the lung alveolar wall and
intestinal mucosa (12). Mouse MCs are classified into connective tissue type
MCs (CTMCs) and mucosal MCs (MMCs). However, MCs are heterogenous and
changes in subtypes can be modulated by environmental factors and differences
in stimuli (3, 13).
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Upon activation, MCs release a diverse range of potent inflammatory mediators
which can be classified into (1) pre-formed mediators including histamine,
serotonin,

renin

and

proteases

such

as

tryptase,

chymase

and

carboxypeptidase-A (2) newly synthesized lipid mediators such as leukotrienes,
prostaglandins and (3) chemokines, growth factors and cytokines including tumor
necrosis factor (TNF), IL-4, IL-5, IL-6, IL-13, macrophage chemotactic protein-1
(MCP-1), platelet-derived growth factor (PDGF), vascular endothelial-derived
growth factor (VEDGF), transforming growth factor (TGF) and fibroblast growth
factor (FGF) (2, 4, 8, 9).

1.1.2. Functions of MCs
The role of MCs in allergy and anaphylaxis has been extensively studied (8, 14,
15). However, MCs play an important role in inflammatory and autoimmune
conditions, as well as in host defense against various pathogens including
parasites, bacteria and viruses (16, 17). Because of their ubiquitous location in
vascularized tissue, MCs are one of the first immune cells to interact with
environmental antigens and pathogens (4). They also play a pivotal role in
maintaining a healthy physiology by promoting innate immunity, angiogenesis
and wound healing (18, 19). MCs are involved in regulating the differentiation of
naïve T-cells, the development of B cells, as well as the migration, recruitment
and activation of dendritic cells, T-cells, neutrophils, eosinophils and monocytes
(20-22). MC-derived histamine and proteases potently induce vasodilatation and
vascular permeability, which enhances the migration of leucocytes to sites of
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inflammation, infection and tissue repair (2, 10). Other MC mediators such as
leukotrienes, proteases and cytokines also act as chemotactic signals for
neutrophils, basophils and eosinophils (23).

MCs also promote the initiation and generation of the adaptive immune response
by expressing both major histocompatibility complex (MHC) class I and class II
proteins via which they present antigens to T cells (24-26).

1.1.3. MCs and Antimicrobial peptides
Antimicrobial peptides (AMPs) such as defensins and cathelicidins are small
positively charged amphipathic molecules, which are crucial in the clearance of
microbial pathogens and thus play an important role in host defense. They
interact with negatively charged phospholipid moieties on microbes resulting in
membrane destabilization, disruption and killing of the offending pathogen (27).
In addition to their anti-microbial properties, AMPs also modulate the immune
system, angiogenesis and wound healing (28-30). In humans, defensins are
characterized into α and β-defensin families depending on the position of
cysteine residues that are involved in disulphide linkages (31). α-defensins are
produced by polymorphonuclear leucocytes and intestinal paneth cells while
human β- defensins (hBDs) are produced primarily by epithelial cells (30). Of the
four members of the hBD family that have been characterized in detail (hBD1-4),
hBD1 is expressed constitutively, while the rest are induced by bacteria, viruses
and cytokines (32). LL-37 is produced by leucocytes as an inactive precursor
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(hCAP18), which is enzymatically cleaved to release the active LL-37. Its gene
expression is induced by infection, inflammation and 1,25-dihydroxyvitamin D3
(33).
MCs interact with AMPs. Both hBDs and LL-37 induce Ca2+ mobilization,
chemotaxis and degranulation in MCs (34-37). Niyonsaba et al showed that
epithelial cell derived hBD2 acts as a chemo-attractant for MCs (38). The same
group also showed that in addition to its anti-microbial properties, LL-37 induces
MC chemotaxis thereby participating in their recruitment to sites of inflammation
(39). MC degranulation mediated by these AMPs results in the release of
mediators such as histamine, which causes vasodilation and increased vascular
permeability resulting in the recruitment of leucocytes and immune cells
necessary for combating the microbial pathogens (40).

1.1.4. MCs and the nervous system
MCs are localized near nerve endings at several anatomical sites such as the
skin, lungs, intestinal mucosa and central nervous system. They interact with
neurons in a bi-directional manner to affect various physiological functions such
as wound healing and stress response (41, 42). Histamine, serotonin and
tryptase released from MCs have an impact on the activity of sensory neurons,
and conversely, MCs are activated by neuropeptides such as calcitonin generelated peptide (CGRP) and substance P (SP) released by nerve terminals of
sensory neurons (43).
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The neuropeptide SP, released from nerve terminals in the central and peripheral
nervous system has a key function in stress response, neurogenic inflammation
and pain (43, 44). Human MCs have been shown to degranulate and release
mediators in response to SP (45-47). Other neuropeptides, which activate MCs
include vasoactive intestinal polypeptide (VIP) and neuropeptide Y (46, 48, 49).

The skin has a very rich supply of sensory nerve endings, which release SP and
other neuropeptides leading to MC degranulation in response to the continuous
exposure to physical as well as emotional stimuli. Therefore, the interaction
between MC and neuropeptides results in the promotion of MC-driven
inflammation and granulocyte infiltration (44, 50).

1.1.5. MCs and wound healing
MCs play pivotal roles in all stages of wound healing: the initial inflammatory
response, revascularization and re-epithelialization of the damaged tissue,
deposition of temporary connective tissue and finally remodeling of the matrix
(23, 51). During wound repair, the MC mediators, histamine, heparin, cytokines
(TNF, IL-6 and IL-8) and growth factors (PDGF, VEDGF, TGF and FGF)
modulate the stages of neovascularization thereby contributing to the regrowth of
the endothelial cells (42, 52). MC mediators histamine, tryptase, TGF and the
cytokines IL-1, IL-4 and TNF are able to stimulate chemotaxis, migration,
phenotypic differentiation and activation of fibroblasts (23). MCs can also
modulate keratinocyte proliferation and migration during the re-epithelialization
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process of wound healing (53, 54) and at the final stages of the wound healing
process, MCs influence the structural re-modeling of newly formed capillaries by
releasing angiogenic factors (55).

1.1.6. MCs and homeostasis
MCs play a role in the control of tissue remodeling. They are involved in the
regulation and maintenance of organs that undergo continuous growth and
structural remodeling such as hair follicles and bones (56). Hair follicle cycling
through periods of rest and growth is impaired in MC-deficient mice and MCderived histamine and TNF have been implicated in regulating hair follicle
transformation from resting to active hair growth (56, 57). MCs also contribute to
bone remodeling. The amount of new bone matrix synthesized in MC-deficient
mice is diminished compared to wild type (WT) mice suggesting that MCs and
their mediators influence the recruitment of osteoblast and osteoclast progenitors
during bone remodeling (58). MCs have also been reported to secrete
osteopontin, a glycoprotein that is involved in immune responses and controls
bone metabolism (59).

1.1.7. MC activation
MCs express the high affinity Fc receptor for IgE known as FcεRI on their cell
surface. During IgE dependent immune responses, activation and degranulation
of MCs occurs with crosslinking of the high affinity receptor by IgE/antigen
complexes (3, 9). In addition to IgE mediated degranulation of MCs, multiple non-
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IgE mediated mechanisms are also known to trigger MC secretion including
activation via the G-protein coupled receptor, Mas-Related Gene X2 (MrgX2)
expressed on MCs.

1.2

Mas-related gene X2 (MrgX2)

1.2.1. What is MrgX2?
The G protein coupled receptors (GPCRs) are one of the largest known family of
transmembrane proteins. Mas–related G protein coupled receptors (Mrgprs)
belong to the GPCR family and are divided into several subfamilies. In humans
four Mrg genes, MrgX1 – MrgX4 are known, while in mice, the Mrg family
comprises of 32 different Mrg coding genes (60). Mrgprs are also referred to as
sensory neuron specific GPCRs because they were originally thought to be
exclusively expressed in dorsal root ganglia (60, 61). However, it has now been
shown that MrgX2 is expressed in LAD2 (a human MC line) and CD34+ cell
derived MCs while human cord blood-derived MCs express both MrgX1 and
MrgX2 (62-64). Also, a higher expression level of MrgX2 mRNA has been
reported in skin-derived cultured MCs compared to lung-derived cultured MCs
(65).

From prior studies on MCs, pertussis-sensitive G proteins have been shown to
be activated by a wide range of endogenous and exogenous polycationic
molecules collectively known as basic secretagogues (66). Neuropeptides such
as SP and VIP are basic secretagogues, which play a role in the pathogenesis of
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chronic urticaria, atopic dermatitis and other inflammatory skin conditions (67,
68).

MrgX2 has now been shown to function as the non-selective, low-affinity binding
site for a wide range of basic secretagogues such as SP, cortistatin (CST),
somatostatin, mast cell degranulating peptide (MCDP), neuropeptide Y,
compound 48/80 and VIP (62, 64, 69, 70). Although these peptides are
structurally unrelated, they are all amphipathic small peptides, which induce
dose-dependent degranulation of human MCs via the activation of MrgX2 with an
associated increase in the intracellular Ca2+ concentration (64, 70).

Subramanian et al also showed that hBDs and the cathelicidin LL-37 activate
human MCs via MrgX2 (32, 63). In their study, LL-37 and the neuropeptide CST
induced sustained Ca2+ mobilization in LAD2 cells and CD34+-cell-derived
primary human MCs, which are known to endogenously express MrgX2.
Substantial MC degranulation with associated increased intracellular Ca 2+
mobilization was induced by hBD2, hBD3 and CST in a rodent MC line, RBL-2H3
stably expressing MrgX2 (32). Therefore, MrgX2 functions as a non-selective
binding site that links these basic peptides to G proteins, leading to the secretion
of histamine and other mediators by MCs (71).

To facilitate in vivo studies on the function, activation and downstream effects of
MrgX2, it is important to identify the mouse counterpart of the human receptor.
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There are significant differences between Mrg receptors in different species.
Human and mouse Mrg receptors share only 45-65% amino acid sequence
identity making it difficult to determine the mouse orthologue (64). In a study by
Subramanian et al, they found that degranulation of murine MCs was resistant to
activation by hBDs while human MCs were susceptible highlighting the possibility
that there may be differences between the human and murine receptors (32).
However, in a recent study by McNeil et al, they reported that basic
secretagogues activated mouse MCs in vitro and in vivo through Mrgbrb2, which
they concluded to be the mouse counterpart of the human MrgX2 receptor (72).

1.2.2. Receptor localization and internalization
Receptor desensitization and internalization are key regulatory mechanisms
involved in GPCR signaling. Activated GPCRs are phosphorylated by a group of
serine/threonine protein kinases known as G protein coupled receptor kinases
(GRKs) with subsequent recruitment of β-arrestin. This results in desensitization
and internalization of the receptors with resultant inhibition of function (73, 74). It
has been reported that MrgX2 is resistant to agonist-induced receptor
phosphorylation, desensitization and internalization, which is contrary to
established reports of the behavior of most GPCRs such as C3aR, the receptor
for the anaphylatoxin C3a (63, 75). In the study by Subramanian et al., MrgX2
was relatively resistant to phosphorylation after stimulation with CST and LL-37
in HEK-293T cells transfected with hemagglutinin (HA)-tagged MrgX2 compared
to C3aR stimulation with the corresponding ligand, C3a. Using Ca2+ mobilization
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assay, they demonstrated that MrgX2 did not undergo desensitization. Instead,
sustained intracellular Ca2+ mobilization was noted in LAD2 cells after stimulation
with CST and LL-37. Also, MrgX2 was not internalized in HMC-1 cells stably
expressing HA-tagged MrgX2 upon stimulation with LL-37 in contrast to C3aR
(63).

Unlike most GPCRs, MrgX2 is expressed intracellularly. Fujisawa et al reported
localization of MrgX2 in the cytoplasm of LAD2 cells and in the same study, they
determined that MrgX2 was expressed intracellularly in human adult peripheral
blood-derived cultured MCs (65).

1.3 MCs and MrgX2 in disease
Under healthy conditions, MC numbers are relatively constant. However, in
inflammatory conditions and infection, their numbers are increased.

1.3.1. Role of MCs and MrgX2 in chronic urticaria
Chronic urticaria (CU) is defined as the presence of daily hives for at least six
weeks (76). MCs are involved in the pathogenesis of CU through the release of
various inflammatory mediators (77, 78). Neuropeptides are also involved in the
pathogenesis of CU. The neuropeptide SP is upregulated in the serum of
patients with chronic spontaneous urticaria (79) and a study has shown that
intradermally injected SP in CU patients led to enhanced and longer lasting
wheal reactions compared with controls (80). Urticaria is associated with
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eosinophil infiltration and the deposition of eosinophil-derived major basic protein
(MBP) (81). Recently, Fujisawa et al. reported that the number and percentage of
MrgX2 positive MCs is increased in the skin of patients with severe chronic
urticaria compared with control subjects (65). Since MBP is a cationic peptide,
which has been reported to activate MCs (82), in the same study by Fujisawa et
al., they investigated the possibility that MrgX2 is the receptor for MBP and found
that MBP induced histamine release from human skin MCs through MrgX2 (65).
Thus, it is likely that MrgX2 expressing MCs are also involved in the
pathogenesis of other inflammatory disease conditions involving MCs including
but not limited to atopic dermatitis, rosacea, periodontal disease and asthma.

1.3.2. Role of MCs in atopic dermatitis
Atopic dermatitis (AD), synonymous with atopic eczema is a chronic
inflammatory relapsing disease of the skin, which often precedes other allergic
disorders such as food allergy, asthma and allergic rhinitis (83, 84). It is the result
of a complex interaction between genetic, immunological and environmental
factors. The onset of AD is usually in early childhood, most commonly between 3
and 6 months of age. However a small percentage of patients develop their first
symptoms in adulthood (85). It affects 15-20% of children and 1-3% of adults
worldwide (86).

The diagnosis of AD is based on a constellation of clinical features, which include
persistent pruritus, age-dependent eczematous eruptions, a chronic relapsing
course, early age of onset, atopy and xerosis (85). Pruritus is often worse at night
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resulting in sleep disturbance and impaired quality of life. The cheeks and scalp
are typically affected in infants, while adolescents and adults usually present with
lichenified plaques affecting the head, neck and flexures (87). Histologically, AD
is characterized by spongiosis which is a non-specific histological pattern seen in
various eczematous reactions.

There is a genetic predisposition to the development of AD. Approximately 70%
of AD patients have a positive family history of atopy (88). Also, the rate of AD is
77% among monozygotic twins compared to 15% in dizygotic twins (89). Loss of
function mutations in the filaggrin gene that result in dysfunction of the skin
barrier are strongly associated with AD (90-92). Filaggrin is involved in
maintaining the epidermal barrier and integrity. Hence filaggrin gene mutations
result in impairment of the skin barrier function with resultant increase in
transepidermal water loss and microbial infections (90). AD patients are therefore
susceptible to colonization and infection with Staphylococcus aureus as well as
herpes simplex virus (HSV) (93).

The expression levels of the AMPs, hBD2 and LL-37 are downregulated in AD
lesions. Both AMPs are involved in the control of microbial infections and are
very potent against the microbes of interest in AD. In addition, they have
chemotactic properties that link the innate and adaptive immune responses and
LL-37 also plays a role in maintaining normal epidermal permeability barrier
function (94). Therefore in AD, the decreased levels of AMPs amplify the
susceptibility to infection as well as the barrier dysfunction.
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In acute lesions of AD, MCs are degranulated but not increased in number.
However, the number of MCs in chronic AD lesions is significantly increased (9598). The increased number of MCs could either be the result of recruitment from
other sites or the proliferation of resident cells (99). Dense dermal infiltration of
MCs was noted in an animal model of AD providing more evidence for their role
in the pathogenesis of AD (100).

MCs may play a role in the pathogenesis of AD by contributing to Th2
polarization in skin lesions of AD patients through the production of IL-4 and IL13. AD is characterized by an increased Th2 response (101) and MCs are a
major source of IL-4 and IL-13 in AD (102, 103). Using an animal model, Spergel
et al showed that IL-4 might play an important role in the inflammation and
hypertrophy of the skin in AD (104). Other mediators of MC degranulation such
as histamine and tryptase contribute to the development of pruritus and skin
barrier defects in AD (90).

Inflammation induced by neuropeptides, which are released from sensory nerves
in response to psychological stress as well as other physical stressors is known
as neurogenic inflammation (105). MCs are able to maintain neurogenic
inflammation in AD through activation by neuropeptides such as SP released by
cutaneous nerves. Jarvikallio et al showed that dermal contacts between MCs
and nerves were increased in number in both lesional and non-lesional skin of
AD patients compared with normal controls. They also found that SP fibers were
more frequent in lesional papillary dermis compared to nonlesional in AD (106).
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On the same note, SP plasma level in AD patients is reportedly higher than in
controls (107).

Eosinophilia is present in most patients with AD and correlates with disease
activity (99). Eosinophil degranulation with significant dermal deposition of
eosinophil-derived MBP in AD has also been demonstrated and also correlates
with disease activity (108). Therefore, we hypothesized that MrgX2 is involved in
the pathogenesis of AD and MCs may be activated by eosinophil-derived MBP
as well as neuropeptides such as SP via MrgX2 resulting in the release of
histamine and Th2 cytokines.

1.3.3. Role of MCs in rosacea
Rosacea is chronic inflammatory cutaneous disorder, which primarily involves the
facial skin. It is a relatively common dermatological condition, which according to
the National Rosacea Society affects approximately 16 million people in the
United States. It affects women more frequently than men (109) with the onset of
symptoms usually occurring between 30-50 years of age (110). A genetic
component has been implicated in the occurrence of rosacea, as there is a
higher incidence in fair-skinned Caucasians compared to those of other
ethnicities (111, 112).

The clinical course of rosacea is characterized by intermittent episodes of
exacerbation

followed

by

remission.

Patients

present

with

variable

symptomatology, which include, non-transient centrofacial erythema, flushing,
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telangiectasia, stinging, burning sensation, dryness, scaling, papules, pustules,
phymatous growths and red watery eyes (113, 114). Based on these clinical
features, rosacea has been classified into four subtypes:
(a) Erythematotelangiectatic rosacea (ETR) characterized by prolonged flushing,
persistent erythema and telangiectasia (b) Papulopustular rosacea, which is
characterized by papules and pustules in addition to the features of ETR (c)
Phymatous rosacea characterized by skin thickening and irregular nodularities
mostly affecting the nose and (d) ocular rosacea characterized by watery
bloodshot eyes, burning and stinging sensation in the eyes (110, 115). Exposure
to ultraviolet light radiation, stress, extremes of temperature and the consumption
of hot beverages, alcohol and spicy foods are some of the known triggers for
rosacea exacerbations (116, 117).

The pathophysiology of rosacea has not been fully elucidated, however it has
been shown to involve dysregulation of the immune, vascular and nervous
systems. Expression levels of the AMP LL-37 has been shown to be upregulated
in patients with rosacea (118, 119). LL-37 has antimicrobial, pro-inflammatory
and angiogenic properties and is induced in keratinocytes by the activation of the
Vitamin D pathway via UV light (120). Likewise, in lesional rosacea skin, there is
increased expression of the epidermal trypsin-like serine protease enzyme,
kallikerin 5 (KLK5), which is responsible for selectively cleaving the inactive
precursor protein (hCAP18) to form the biologically active LL-37 (119, 121, 122).
Also found in rosacea skin are abnormal peptide fragments of both LL-37 and
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KLK5, which are more pro-inflammatory and differ from those found in healthy
skin (119). The expression of toll-like receptor 2 (TLR2), which is an innate
immune system pattern recognition receptor is increased in rosacea. TLR2 is
possibly activated by environmental factors and structural molecules on microbes
such a chitin released from Demodex mites, which are commensal mite species
ubiquitous to human skin. Elevated TLR2 expression in rosacea results in
increased production of KLK5, which cleaves hCAP18 leading to the production
of LL-37 (123, 124). Thus LL-37 plays a central role in the pathogenesis of
rosacea.

MCs have been shown to be involved in the pathogenesis of rosacea. Studies
have revealed significantly greater number of MCs in rosacea lesions compared
to non-lesional skin (125, 126). In addition to keratinocytes and neutrophils, LL37 is also produced from MCs (127). In a study by Muto et al, MC deficient mice
did not develop inflammation following LL-37 injection whereas WT mice
developed rosacea-like inflammation (128). In the same study they also showed
that activation of MCs by LL-37 led to the secretion of MC proteases. MMP-9 is
secreted by activated MCs and is upregulated in rosacea (128, 129). MMP-9
cleaves the precursor of KLK5 into the active form of KLK5 also leading to the
generation of LL-37. Therefore both LL-37 and MCs play critical roles in the
pathogenesis of rosacea.
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Neurogenic inflammation mediated by multiple neuropeptides such as SP, VIP
and pituitary adenylate cyclase-activating peptide (PACAP) has been associated
with rosacea flare-ups. MCs release their contents upon activation by
neuropeptides. In an immunohistochemistry study by Wollina et al, there was a
denser distribution of the VIP receptor positive cells in rosacea lesions compared
to controls showing the VIP may contribute to the pathophysiology of rosacea
(130). Increased expression of SP has also been reported in rosacea lesions
(131). Likewise, tryptase mRNA expression was significantly increased by
PACAP stimulation in WT mice compared to MC deficient mice (128). Thus, the
findings that (a) MC numbers are increased in rosacea (b) expression levels of
LL-37 is upregulated in rosacea (c) neurogenic inflammation mediated by
neuropeptides is associated with rosacea flare-ups and (d) both LL-37 and
neuropeptides are MrgX2 ligands suggest that MrgX2 expressed in MCs
contribute the pathogenesis of rosacea. However, it is unknown if MrgX2 is
expressed in skin of rosacea patients.

1.3.4. Role of MCs in periodontal diseases
The periodontium consists of the gingiva, periodontal ligament, cementum and
alveolar bone. Periodontal disease refers to a group of inflammatory conditions
that affect these structures. Gingivitis is the form of periodontal disease, which
involves the gingiva and is not associated with destruction of the periodontal
ligament or alveolar resorption while periodontitis involves destruction of the
attachment apparatus. Chronic periodontitis (CP) is an infectious disease, which
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results in progressive attachment and bone loss as a consequence of
inflammation within the supporting tissues of the teeth.

Dental plaque is considered the principal etiological factor for periodontal
disease as a result of colonization of the gingival sulcus by microorganisms
within the dental plaque, which promote an inflammatory response in the
periodontal tissues. However, the pathogenesis of periodontal disease involves a
complex multifactorial interaction between plaque microorganisms and the host
response. Various social, behavioral, systemic and genetic factors can modify
the susceptibility of the host to periodontal disease.

Both inflammatory and

immunologically mediated pathways are upregulated in the presence of bacterial
plaque resulting in the production of pro-inflammatory mediators by cells of the
immune system, which are subsequently responsible for causing the damage
seen in periodontal disease.

MCs are thought to be involved in the pathogenesis of periodontal disease.
Studies by Huang et al showed a correlation between MC density, degree of
degranulation and the severity of human periodontitis (132). Other studies have
also documented an increase in the number of MCs in the gingiva of patients
with periodontal disease compared with clinically healthy gingival tissue (133,
134). Activated MCs release histamine, proteases, cytokines and other
mediators, which perpetuate the immune response and contribute to the healing
process as well as the destructive process.
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The AMPs such as hBDs, which are produced by epithelial cells activate human
MCs via MrgX2 (32). A study by Lui J.et al reported significantly higher basal
hBD3 expression in keratinocytes from periodontitis patients compared with
healthy controls (135). LL-37, a cathelicidin derived from neutrophils activates
human MCs via MrgX2. Expression of LL-37 is increased in gingival crevicular
fluid of patients with chronic periodontitis compared with healthy subjects (136,
137). These findings suggest that AMPs may play facilitate the immunological
response in chronic periodontitis through the activation of MCs via MrgX2.
However, the possibility that human gingival tissue MCs express MrgX2 has not
been tested.

1.3.5. Role of MCs in asthma
Asthma is a multifaceted airway inflammatory disease characterized by
reversible airflow obstruction, airway inflammation, persistent airway hyperresponsiveness and airway remodeling which results in recurring incidents of
wheezing, breathlessness, chest tightness and coughing (138-140). According to
the Centers for Disease Control and Prevention (CDC), asthma affects 7.3% of
Americans with the burden of disease resulting in reduced quality of life,
hospitalizations and deaths.

The etiology of asthma involves a complex interplay between genetic and
environmental factors. Allergic or extrinsic asthma, which is the most common
form of asthma, is triggered by inhaled allergens such as pollen, dust, mites and
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animal dander. Sensitization occurs upon initial exposure to an allergen and on
subsequent exposure to the same allergen, the clinical symptoms of asthma
occur. During sensitization, inhaled allergen is intercepted by dendritic cells,
which function as antigen presenting cells. The antigen is processed by dendritic
cells and subsequently presented to antigen-specific T-cells, which secrete
cytokines that stimulate B cells to undergo class switching to IgE-producing B
cells. The Fc portion of the circulating IgE then binds to MCs and basophils via
the high affinity Fc receptor for IgE known as FcεRI on their cell surfaces. Upon
re-exposure to the sensitizing allergen, activation and degranulation of MCs
occurs with crosslinking of the high affinity receptor by IgE/antigen complexes
resulting in the release of inflammatory mediators, which initiate an immediate
acute phase reaction manifested as bronchospasm (140, 141).

MCTC are more prominent in skin while normal human lung MCs are
predominantly of the MCT phenotype with the minority being MCTC. These MCT
are found in the alveolar wall and epithelium of the lung while MC TC are
preferentially located in the bronchial smooth muscles and glandular areas (142).
However, markedly increased numbers of MCTC are present in the bronchial
smooth muscles of patients with severe asthma (143-146). It has been shown
that normal skin MCs which are typically MCTC express GPCRs for MrgX2 while
normal lung MCs do not express these receptors (147). These findings suggest
that MrgX2 expressed in asthmatic lung MCTC could participate in the
pathogenesis of asthma.
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Human rhinovirus (HRV) and Respiratory syncytial virus (RSV) which exacerbate
asthma symptoms in children (148) are associated with increased induction of
hBDs in bronchial epithelial cells (149-152). Therefore, it is possible that these
hBDs activate MCTC in the bronchial smooth muscles of asthmatic patients via
MrgX2 leading to the exacerbation of their symptoms. Neutrophils and
eosinophils are known to play important roles in the late phase of allergic asthma
(153). Subramanian et al., showed that neutrophil-derived AMP, LL-37 activate
human MCs via MrgX2 (63). Furthermore, Fujisawa et al. showed that cationic
peptides released from activated eosinophils cause degranulation in MCTC-type
MCs via MrgX2 (65). These findings raise the interesting possibility that MrgX2
expressed in lung MCTC contributes to the pathogenesis /exacerbation of asthma.
However, it is unknown if human lung MCs express MrgX2 and if their expression
is modulated during asthma.

1.4 Humanized mice as a model for in vivo studies on MrgX2
Studies have shown that MrgX2 is activated by small cationic peptides such as
neuropeptides and AMPs. However, no in vivo functional studies have been
carried out primarily due to the fact that MrgX2 is not expressed in mice. Also,
studies by Subramanian et al showed that known MrgX2 ligands do not activate
murine MCs (32, 63). Therefore, new models need to be developed to study the
biology of human MrgX2 in vivo.

One of the most exciting recent advances in translational research has been the
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development and utilization of humanized mice to study the role of human
lymphoid and myeloid cells in vivo (154-158). It is well documented that the
receptor for the murine SCF, c-kit is important for the development of murine
MCs. Kambe et al., (159) provided the first demonstration that engraftment of
human HSCs, (CD34+ cells) into severely immune deficient mice leads to the
development of some human MCs in mouse lung and skin indicating that mouse
endogenous SCF is able to support human MC development to a certain extent.
However, functional characterization of these MCs has not been performed.
More recently, a new model has been developed in which an immune-deficient
mouse (NOD, SCID, IL2 receptor --null; NSG) expresses three transgenes;
human SCF, GM-CSF and IL-3, each driven by a human cytomegalovirus
promoter/enhancer and constitutively produce 2 - 4 ng/ml of these human
cytokines in the serum (NSG-SGM3) (160, 161). Given that SCF and IL-3 are
important growth factors for human MCs, we predicted that these mice will serve
as “incubators” for the differentiation of human CD34 + cells into MCs. Therefore
one of the aims of this study was to do an initial assessment of the feasibility of
utilizing humanized mice as a model for in vivo functional studies on MrgX2, as
well as mouse models to determine the role of MrgX2 in human disease
conditions involving MCs.
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2. RESEARCH AIMS
Objectives
There are three objectives of the present study:
1) To determine if human skin, gingival and lung MCs express MrgX2 and to test
if its expression is upregulated in human disease conditions such as AD,
rosacea, chronic periodontal disease and asthma.

2) To investigate the localization of MrgX2. To determine if the receptor is
localized to the plasma membrane, cytoplasm or both and to further evaluate if
the localization changes on stimulation.

3) To test if human MCs that develop in humanized mice express MrgX2.

3. MATERIALS AND METHODS
3.1 Sample Collection
The study protocols for the expression of MrgX2 by human skin and gingival
tissues were approved by the Institutional Review Board (IRB) of the University
of Pennsylvania. The IRB protocol number for the gingival study is 822486 and
for the skin study, it is 808225. The gingiva study was conducted using pieces of
otherwise discarded gum tissue that were removed during the normal course of
periodontal surgery on patients at the Graduate Periodontics Clinics, School of
Dental Medicine, University of Pennsylvania. Written informed consent was
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obtained from all patients prior to collection of the gingiva samples. The
discarded tissue were collected in an anonymous fashion without any patient
identifiers and transported to the Department of Pathology in10% formalin where
they were processed and cut into tissue blocks. Skin samples used in this study
were archival tissue samples of patients provided by the Penn Skin Disease
Research Center while the human lung samples were provided by Dr. Reynold
Panettieri (Airway Biology Program, School of Medicine, University of
Pennsylvania).

3.2 Materials
All cell culture reagents were purchased from Invitrogen (Gaithersburg, MD).
Amaxa transfection kit (Kit V) was purchased from Lonza (Gaithersburg, MD).
Cortitastin (CST) – 14 was obtained from American Peptide (Vista, CA). LL-37
was from Anaspec (Freemont, CA) and SP was from American Peptide
Company (Sunnyvale, CA). Rabbit anti-Mrgx2, catalog #: NB110-75035 was
purchased from Novus Biologicals (Littleton, CO). Mouse anti-human tryptase,
catalog #: sc-33676 was purchased from Santa Cruz (Dallas, TX). Anti-HA
mouse monoclonal antibody, catalog #: 11583816001 was purchased from
Roche Diagnostics (Mannheim, Germany). Donkey anti-mouse secondary
antibody, Alexa Fluor 488, catalog #: A21202 was purchased from ThermoFisher
Scientific (Grand Island, NY). Donkey anti-rabbit secondary antibody, Alexa Fluor
594, catalog #: A21207 was purchased from ThermoFisher Scientific (Grand
Island, NY). 4’,6-diamidino-2-phenylindole (DAPI) was obtained from Invitrogen
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(Grand Island, New York). ProLong Gold antifade reagent was purchased from
Invitrogen (Grand Island, NY). Target retrieval solution was purchased from Dako
(Carpinteria, CA). Mouse IgG Vectastain ABC kit, catalog #: PK-4002 was
purchased from Vector Laboratories (Burlingame, CA). 3,3’-diaminobenzidine
(DAB) peroxidase substrate kit, catalog #: SK-4100 was purchased from Vector
Laboratories (Burlingame, CA).

3.3 Methods
3.3.1. Immunohistochemistry
Immunohistochemistry (IHC) experiments were performed on human normal and
diseased skin, gingiva and lung tissue as well as humanized mice lung samples
to show the presence of MCs in the samples. Diseased tissue samples were
from patients diagnosed with AD, rosacea, CP and asthma. Tryptase was used
as the MC marker for all experiments. Tissue samples were fixed in 10% formalin
for 24 hours and subsequently embedded in paraffin and sectioned to 5 μm
thickness on charged slides (2 sections per slide). The slides were heated to
55oC overnight, subsequently deparaffinized in Histoclear and hydrated in a
series of graded ethanol incubations. Antigen retrieval was performed by heat
treatment using 1X antigen retrieval solution in a water bath at 95oC for 1hour.
The slides were placed in a humidified chamber and peroxidase quenching was
achieved with 0.3% H202 blocking solution for 10 minutes at room temperature
followed by 2 washes in PBS. The slides were incubated for 1hour at room
temperature with blocking serum using normal horse serum followed by
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incubation with primary antibody (anti-human tryptase) at a dilution of 1:750
overnight at 4oC in a humidified chamber. For negative control, serum blocking
reagent was used in place of primary antibody on the first section of all slides.
The sections were then washed 3 times with PBS/0.1% Tween and incubated
with diluted secondary antibody, biotinylated horse anti mouse IgG for 30
minutes at room temperature. Following incubation with secondary antibody, they
were washed 3 times in PBS/0.1% Tween and incubated for 30 minutes with
Vectastain ABC reagent. Subsequently, they were washed 3 times in PBS/0.1%
Tween and incubated in peroxidase substrate solution using DAB peroxidase
substrate kit until desired color intensity was observed. The slides were rinsed
under running tap water for 5 minutes, counterstained in Mayer’s hematoxylin
solution for 30 seconds and rinsed again in running tap water until excess
solution was removed. Rehydration of the tissue was done using increasing
graded alcohol series followed by Histoclear solution. The slides were allowed to
air dry before mounting with Permount mounting medium. Images were captured
on a Nikon Eclipse microscope with an Olympus digital microscope camera using
4X, 10X and 20X objectives.

3.3.2. Immunofluorescence
Tissue Samples
Immunofluorescence (IF) experiments were performed on the same tissue
samples

as

IHC

experiments.

Tissue

preparation,

sectioning

deparaffinization were performed as described above for IHC.

and

The tissue
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samples were subsequently incubated with blocking buffer [5% normal donkey
serum, 0.3% of Triton X-100 in phosphate buffered saline (PBS)] for 1hour at
room temperature. Incubation with primary antibody (anti-human tryptase) was
carried out in antibody dilution buffer (PBS with 1% bovine serum albumin and
0.3% Triton X-100) overnight at 4oC at a dilution of 1:500. For negative control,
antibody dilution buffer was used in place of primary antibody on the first section
of all slides. The sections were then washed 3 times with PBS and incubated
with secondary antibody, Alexafluor 488-conjugated donkey anti-mouse (1:400)
in conjunction with DAPI (1:4000) for 1 hour at room temperature in the dark.
Tissue sections were washed 3 times with PBS and incubated overnight at 4 oC
with anti-human MrgX2 primary antibody at a dilution of 1:500. The sections were
again washed 3 times with PBS and incubated in the dark at room temperature
with secondary antibody, Alexa flour 594-conjugated donkey anti-rabbit at a
dilution of 1:400. The tissues were washed 3 times in PBS and mounted with
ProLong Gold antifade reagent. Images were captured on a Nikon Eclipse
microscope with an Olympus digital microscope camera using 20X and 40X
objectives.

3.3.3. Transfection of RBL-2H3 cells
RBL-2H3 cells were transfected with plasmids encoding HA-tagged MrgX2 using
the Amaxa nucleofector device and Amaxa kit V, according to the manufacturer’s
protocol (32, 62). Following transfection, a proportion of the transfected RBL-2H3
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cells were stimulated with CST for 5 minutes and used in immunofluorescence
experiments to evaluate the effect of stimulation on the localization of MrgX2.

Immunofluorescence on RBL-2H3 cells expressing HA-tagged MrgX2
Stimulated and unstimulated RBL-2H3 cells transiently expressing HA-tagged
MrgX2 were counted and diluted in PBS. Cytospin slides were labeled and
prepared by attaching plastic cytospin funnel and slide to cytospin clip. 100μl of
the diluted cells were pipetted into each section of the cytospin funnel. The slides
were centrifuged at 450rpm for 5 min, left to air dry, then fixed in 100% ice-cold
methanol for 10 min, followed by rinsing in PBS. The cells were permeabilized
with 0.5% saponin in PBS for 10 min, washed 3 times in PBS, blocked with 5%
donkey serum for 1 hour at room temperature and washed again in 3 changes of
PBS. The cells were incubated overnight at 4OC with anti-HA mouse monoclonal
antibody diluted in antibody dilution buffer at a dilution of 1:500. The cells were
washed 3 times in PBS and incubated with secondary antibody, Alexafluor 488conjugated donkey anti mouse (1:400) in conjunction with DAPI (1:4000) for 1
hour at room temperature in the dark. This was followed by 3 times washing in
PBS and mounting with ProLong Gold antifade reagent. Images were captured
on a Nikon Eclipse microscope with an Olympus digital microscope camera using
20X objective.
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3.3.4. Degranulation
RBL-2H3 cells (5 X 104) stably expressing MrgX2 were seeded into 96-well
plates in a total volume of 50μl HEPES buffer containing 0.1% BSA and exposed
to the peptides LL-37 and SP at 5μM and 10μM. For total β-hexosaminidase
release, unstimulated cells were lysed in 50μl of 0.1% Triton X-100. Aliquots
(20μl) of supernatant or cell lysate were incubated with 20μl of 1mM pnitrophenyl-N-acetyl-β-D-glucosamine for 1.5 hours at 370C. Reaction was
stopped by adding 250μl of a 0.1 M Na2C03/0.1 M NaHC03 buffer and
absorbance was measured at 405nm (32, 63).

3.3.5. Cell Counting and Analysis
Expression of MrgX2 by MCs in human skin
Skin samples from 3 patients diagnosed with AD, 2 patients diagnosed with
rosacea and 3 control patients were analyzed by IF to evaluate the differences in
number of skin MCs as well as differences in the expression of MrgX2 by skin
MCs. Pictures were taken from 5 randomly selected visual fields in each skin
sample at a magnification of 40X. The image exposure, size and dimensions
were exactly the same for all analyzed images. MCs were identified using
tryptase antibody and were stained green. MrgX2 positive cells were red in color.
The number of MCs and were counted in the 5 visual fields and the average of
the 5 fields was taken as the final count of MCs for that sample. Differences in
the expression of MrgX2 by MCs were also evaluated. Intensity of tryptase
expression by MCs as well as intensity of MrgX2 expression in the same MCs
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was evaluated using Metamorph image analysis software. Using colocalized
images, the intensity of the green tryptase staining by MCs as well as red MrgX2
staining in MrgX2-positive MCs was measured. Image exposure was exactly the
same for all analyzed images. The intensity values were normalized by the area
of the MCs and an average intensity value was calculated for each skin sample
analyzed.

Expression of MrgX2 by MCs in human gingiva
Gingiva tissue samples from 3 patients diagnosed with CP and 1 control patient
who did not have CP were evaluated qualitatively for the expression of MrgX2 by
gingiva MCs due to small sample size.

Expression of MrgX2 by MCs in human lung
Lung tissue samples from 6 patients who died from complications of asthma and
6 control subjects who died from other causes were analyzed by IF to evaluate
the differences in number of lung MCs, MrgX2-expressing cells, as well as
MrgX2-positive MCs. Pictures were taken from 3 randomly selected visual fields
in each lung sample at a magnification of 20X. The image size and dimensions
were exactly the same for all analyzed images. MCs were identified using
tryptase antibody and were stained green. MrgX2-positive cells were red in color.
The number of MCs, MrgX2 positive cells, as well as MrgX2-positive MCs was
counted in the 3 visual fields and the average of the 3 fields was taken as the
final count for that sample.
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Expression of MrgX2 in humanized mouse lung MCs
Immune-deficient mice transgenic for human cytokines (NSG-SGM3) mice (3 -4
weeks old) were preconditioned with busulfan (Sigma, 30 mg/kg, I.V.) or
sublethally irradiated (150 cGy). The following day, purified human cord bloodderived CD34+ cells (2 x 105 cells) were injected via tail vein. After 12 weeks
mice were euthanized and lung preparations were used for IHC and IF studies to
determine if human MCs develop in these mice and if they express MrgX2.

3.3.6. Statistical analysis
GraphPad Prism scientific software was used for statistical analysis. Differences
in the number of skin MCs as wells as differences in the expression of MrgX2 by
skin MCs were evaluated by using the unpaired student t-test. Differences in the
numbers of lung MCs, MrgX2-positive cells and MrgX2-positive MCs in the lungs
were also evaluated by using the unpaired student t-test.

4. RESULTS
4.1 Expression of MrgX2 in skin samples of patients with AD and Rosacea.
AD is an inflammatory disease that involves MCs and eosinophils (96, 108).
Previous studies have shown that MrgX2 is expression in human skin MCs and
their activation by eosinophil-derived peptides contributes to the pathogenesis of
another inflammatory skin disease; CU (65). Our first goal was therefore to
determine if MCs from patients with AD also express MrgX2. For all studies
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described here and in the sections below with human tissue samples, we utilized
two approaches to study MCs and MrgX2. First, we used IHC with an antitryptase antibody in combination with hematoxylin and eosin (H & E) to
determine the presence of MCs in relation to structural cells in skin. Second, we
utilized a three-color IF approach to determine the expression of MrgX2 (red),
MCs (green) in the context of the nucleus (blue). Using IHC, we found that MCs
are present in the dermal layers in both healthy (Fig. 1A and B) and diseased
(Fig. 1C and D) skin tissue compared to the epidermis. Using IF, we found that
Mrxg2 is expressed in normal and AD skin samples (Fig. 2B and D).
Furthermore, staining of the same sample with anti-tryptase antibody showed
that the same cells are MCs. When the MrgX2 and tryptase panels were merged,
it clearly showed that MCs in normal and AD skin samples express MrgX2.
However, there was a greater intensity of colocalization in the diseased samples
compared to the normal samples which could indicate that MrgX2 expression by
MCs is more active in AD compared to healthy skin (Fig. 2B and D). Using IF,
we quantitated the number of MCs and found that the number of MCs (tryptasepositive green cells) was not significantly different in skin tissues from control
subjects compared with AD patients (Fig. 3). The intensity of tryptase-positive
green cells was also not significantly different in skin tissues from control
subjects compared with AD patients (Fig. 4A). The expression of MrgX2 by
MrgX2-positive MCs was also evaluated and there was no significant difference
in the intensity of the red staining by MrgX2-positive MCs between the 2 groups
(Fig. 4B). Of note is the fact that the control skin samples in this study were taken
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from scar tissue. MCs play key roles in wound healing. Therefore, it is possible
that the MCs in the control samples were also increased in number and activity
resulting in similar results between the two groups.

MCs and LL-37 are key players in the pathogenesis of rosacea (118, 125).
Neurogenic inflammation is associated with rosacea flare-ups. Prior studies have
shown that LL-37 and neuropeptides such as SP activate human MCs via MrgX2
(63, 64). Therefore we sought to determine if MCs from patients diagnosed with
rosacea express MrgX2. Similar to AD, MCs are present in the dermal layers in
both healthy (Fig. 5A and B) and diseased (Fig. 5C and D) skin tissue compared
to the epidermis. As shown in Fig. 6D, MCs in the skin of rosacea patients
express MrgX2. There is also a greater intensity of colocalization between green
cells (MCs) and red cells (MrgX2) in the diseased skin sample (Fig. 6D)
compared to the normal skin (Fig. 6B) possibly indicating greater activity of
MrgX2 in MCs in rosacea skin compared to healthy skin. Using IF for
quantitation, we found that the number of skin MCs was not significantly different
in skin samples of control subjects compared with rosacea patients (Fig. 7).
Although there was a significant reduction in the intensity of tryptase-positive
green cells in skin tissues from rosacea patients compared with controls
(P=0.0260) (Fig. 8A), the expression of MrgX2 by tryptase-positive MCs was
evaluated and there was no significant difference in the intensity of the red
staining by MrgX2-positive MCs between the 2 groups (Fig. 8B). Tryptase is a
protease found in MCs, which is released on degranulation. MC degranulation
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plays a direct role in the pathogenesis of rosacea (115). Taken together, these
results indicate that although the MC numbers are not significantly different
between the groups, there is an increased degranulation of MCs in rosacea
resulting in a significant reduction of the intensity of green tryptase-positive MCs
in rosacea skin. Furthermore, although the intensity of green tryptase-positive
MCs is reduced in rosacea, the expression of MrgX2 by MrgX2-positive MCs was
not significantly different between the groups indicating that there is a higher
activity of MrgX2 in MCs in rosacea skin compared to healthy skin.

4.2 Expression of MrgX2 in normal gingiva and gingiva from patients with
CP
MCs and AMPs are involved in the pathogenesis of periodontal disease (132,
136). Since AMPs have been shown to activate MCs via MrgX2, we sought to
determine if MrgX2 is expressed by gingival MCs. IHC and IF analysis were
performed on gingiva tissue samples from three patients diagnosed with CP as
well as a control subject not diagnosed with CP.

On IHC, most MCs were

observed in the lamina propria and submucosa in both healthy (Fig. 9A and B)
and diseased (Fig. 9C and D) gingiva tissue compared to the epithelium.
However, gingiva samples from patients with CP showed increased number of
MCs in the epithelium compared to the healthy gingiva indicating that MCs
migrate into the epithelium in disease. With IF, we found that Mrxg2 is expressed
in healthy and CP gingiva samples (Fig. 10B and D). Furthermore, as shown in
Fig. 10B and D, MCs are present in the human gingival tissue and these cells
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express MrgX2. Due to small sample size (3 CP patients and 1 control), we did
not do a quantitative analysis. However, as noted in the skin samples, there was
also a more intense colocalization in the CP gingiva compared to normal gingiva.

4.3 Expression of MrgX2 in normal and asthmatic lung
MCTC are markedly increased in the bronchial smooth muscle during asthma
(144, 146). IHC and IF analysis were performed on lung tissue from patients who
died from asthma related complications as well as control samples of lung tissue
from subjects who died from other causes. IHC was performed on lung tissue
from both groups using human anti-tryptase antibody. As shown in Fig. 11, more
MCs are observed in the lung smooth muscle of patients who died from asthma
complications (Fig. 11C and D) compared with control subjects (Fig. 11A and B).

Although it well established that MCs are present in human lung tissue, it is
unknown if these cells express MrgX2. Furthermore, outside the dorsal root
ganglia, MCs are the only cells that have been shown to express MrgX2 (60, 62,
63). To determine if human lung tissue express MrgX2 and if they are found in
MCs, IF study was performed using anti-MrgX2 and anti-tryptase antibodies. As
shown in Fig. 12, MrgX2 (red) and MCs (green) could be detected in normal (Fig.
12B) and diseased (Fig. 12 D) human lung tissue. Merging of the images
revealed that these MCs express MrgX2. The number of lung MCs was
significantly greater in lung tissue from patients who died from asthma
complications compared with individuals who died from other causes (P= 0.0178)

46

(Fig. 13A). The number of MrgX2- positive cells was also significantly greater in
lung tissue from patients who died from asthma complications compared with
control subjects (P= 0.0211) (Fig 13B). Furthermore, there were MrgX2-positive
cells that were not tryptase-positive MCs as shown in Fig. 12D. There were also
a few MCs, which were not MrgX2-positive but this was not significant between
the two groups. Next, we compared the number of MrgX2-positive MCs between
the groups and found a significant increase in the number of MrgX2-positive MCs
in lung samples of patients who died of asthma complications compared to
controls (P= 0.0176) (Fig. 14). These results indicate that MrgX2 is involved in
the pathogenesis of asthma.

4.4 MrgX2 localization
Most GPCRs are expressed on the plasma membrane and are internalized after
stimulation (162). However, it has been reported that MrgX2 is expressed on the
plasma membrane as well as intracellularly (65). Furthermore, MrgX2 is resistant
to agonist-induced receptor phosphorylation, desensitization and internalization
(63). This study evaluated the localization of MrgX2 before and after stimulation
with the basic secretagogue CST. IF experiments were performed on RBL-2H3
cells transiently expressing HA- tagged MrgX2 using anti-HA antibody for the
detection of MrgX2.

As shown in Figure 15, MrgX2 is present on the plasma membrane as well as the
cytoplasm. On stimulation with CST, the receptor remained on the plasma
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membrane as well as in the cytoplasm but with a more peri-nuclear and punctate
appearance.

4.5 Effects of LL-37 and SP-induced degranulation on RBL-2H3 cells stably
expressing MrgX2
Excessive production of LL-37 as well as dysregulation of MC activity have been
implicated in the pathogenesis of rosacea (118, 125). In both rosacea and AD,
MCs are able to maintain neurogenic inflammation through activation by
neuropeptides such as SP (131, 163). MrgX2 has been shown to function as a
binding site for a wide range of unrelated basic peptides including SP and LL-37,
leading to the degranulation of MCs (63, 64). Therefore, our goal was to show
that ectopic expression of MrgX2 in RBL-2H3 cells makes these cells responsive
to LL-37 and SP resulting in degranulation. It should be noted that without
transfection of the corresponding cDNA encoding the receptor, RBL-2H3 cells do
not endogenously express MrgX2 and are unresponsive to LL-37 and SPinduced degranulation.

As shown in Fig. 16, stimulation by LL-37 and SP

induced dose-dependent degranulation in RBL-2H3 cells stably expressing
MrgX2.

4.6 Expression of MrgX2 in humanized mouse lung tissues
Very few MCs are present in the mouse bronchioles and lung parenchyma.
However, engraftment of human HSCs into severely immune deficient mice
transgenic for human cytokines (humanized mice) leads to the development of
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human MCs in mouse tissues (159). The possibility that these mice develop
human MCs in mouse lung and if they express MrgX2 have not been determined.
First, we used NSG-SGM3 mice preconditioned with busulfan before engraftment
of human HSCs. Our IHC study with tryptase antibody demonstrated that human
MCs develop in the lung of humanized mice (Fig. 17A). We used IF analysis to
determine if these MCs express MrgX2. As shown in Fig. 17B, MrgX2 is
expressed in the lung of humanized mice and this receptor is expressed on
human MCs. Similar results were obtained with NSG-SGM3 preconditioned by
irradiation before engraftment of human HSCs (Fig 18 A and B).

5. DISCUSSION
Mrg receptors belong to the GPCR family. In humans, four MrgX genes, MrgX1 –
MrgX4 have been identified while mice have 32 Mrg coding genes (60). As a
result, human and mice Mrg receptors share only 45-65% amino acid sequence
identity (64). Studies have shown that a wide variety of biologically relevant
cationic peptides including neuropeptides and AMPs induce dose-dependent
degranulation of MCs via MrgX2 (32, 63, 64). To the best of our knowledge,
expression of MrgX2 has been reported only in dorsal root ganglia and MCs (64,
65, 69). Given the recent report that expression of MrgX2 on MCs is upregulated
in skin of patients with severe chronic urticaria, we hypothesized that MrgX2 is
also expressed on human lung and gingival MCs. We further hypothesized that
its expression will be increased in AD, rosacea, CP and asthma.
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MCs are granule containing immune cells with varied functions in both health and
disease. They are more abundant at sites that are continuously exposed to the
external environment and are usually located beneath the epithelium adjacent to
blood vessels and in proximity to nerve fibers (4). In the physiological state, MCs
are key players in promoting innate immunity and host defense against various
pathogens (6, 56). They are also involved in maintaining normal homeostasis as
well as angiogenesis and wound healing (5, 44). In the adaptive immune
response, MCs play a role in regulating the development of B cells as well as the
differentiation of naïve T cells (20, 21). MCs interact with AMPs and
neuropeptides. hBDs and LL-37 induce Ca2+ mobilization, chemotaxis and
degranulation in MCs resulting in the release of mediators (32). Neuropeptides
such as VIP, CGRP and SP released by nerve terminals also activate MCs
leading to degranulation.

Under physiological conditions the skin and gingiva are constantly exposed to
pathogens. hBDs and LL-37 are potent AMPs produced by activated epithelial
cells and neutrophils respectively (30). They exhibit antimicrobial properties
against a wide variety of microorganisms. hBDs are produced by epithelial cells
in response to exposure to infectious agents which they kill by binding to
negatively charged phospholipid residues on their membrane thereby forming
pores (164). Since hBDs activate MCs via MrgX2, this raises the interesting
possibility that upon exposure to pathogens, epithelial cells produce hBDs, which
activate MCs resulting in the secretion of MC-mediators. MC degranulation and
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release of mediators such as histamine leads to increased vascular permeability
and promotes the recruitment of leucocytes, which contribute to microbial killing
by phagocytosis (165). Furthermore, the recruited neutrophils release LL-37,
which also activate MCs via MrgX2 thereby contributing to host defense through
activation of more MCs and recruitment of more neutrophils. Therefore, it
appears that MrgX2 expressed on MCs facilitates vascular permeability and
neutrophil recruitment and plays a central role in orchestrating host defense by
functioning as an important link between the epithelium and neutrophils.
Interestingly, AMPs and MCs are both involved in modulating the immune
system, angiogenesis and wound healing (23, 166, 167). The skin, which is
highly innervated, is also continuously exposed to external stimuli during the
physiological state. The neuropeptide SP released by nerve endings in response
to physical and emotional stimuli activate MCs via MrgX2 with the resultant effect
of increased vascular permeability and granulocyte infiltration.

MCs play important roles in host defense and wound healing but their
inappropriate activation leads to allergic and inflammatory disease. MCs are
known to be involved in chronic inflammatory conditions, which involve AMPs
and neuropeptides. Therefore, in disease conditions such AD, rosacea, CP and
asthma MC activation leads to undesirable clinical manifestations.

This study has demonstrated that MCs in both healthy and diseased skin express
MrgX2. In the skin of patients diagnosed with AD, the number of MCs was not
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significantly different compared to control subjects. Also, there was no difference
in the expression of MrgX2 by MrgX2-positive MCs between the groups. The
results may be explained by the fact that in healthy conditions, MC TC, which are
known to express MrgX2 are prominent in the skin and so do not need to be
recruited to the skin in AD. It is more likely generation of ligands such as SP and
MBP secreted from recruited eosinophils contribute to the symptoms associated
with AD via the activation of MrgX2 expressed in MCs. It is noteworthy that the
control skin samples used in our study were taken from scar tissue and MCs are
known to play a very important role in wound healing. This was done because we
did not have access to normal human skin samples. It is therefore possible that
the control we used had elevated number of MCs making to difficult to assess the
MC numbers in control and AD samples. Nevertheless, the presence of MrgX2 in
MCs of skin samples taken from AD patients suggests that MrgX2 contributes to
the pathogenesis of AD.

We also evaluated the expression of MrgX2 by MCs in the skin of patients with
rosacea, which is a chronic inflammatory skin disorder that involves MCs and
found that these MCs express MrgX2. Furthermore, we compared the number of
MCs in rosacea skin with control skin and found no significant difference between
the groups. However, there was a significant reduction in the expression of
tryptase-positive MCs in the rosacea group, which could indicate that the
reduced expression of tryptase by MCs in the rosacea group is due to
degranulation of MCs. In spite of the reduced tryptase expression by MCs in the
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rosacea group, there was no significant difference in the expression of MrgX2 by
MrgX2-positive MCs between the groups signifying greater activity of MrgX2 in
MCs in rosacea skin compared to control. LL-37 plays a central role in the
pathogenesis of rosacea (118). Furthermore, increased expression of SP has
also been reported in rosacea lesions (131). Therefore, we propose that MC
activation and degranulation by LL-37 and SP via MrgX2 contribute to the
pathogenesis of rosacea.

The expression of MrgX2 by gingival MCs from healthy and periodontally
involved gingiva was assessed showing that MCs from both groups express
MrgX2. We did not evaluate differences in MC numbers due to very small sample
size. Studies have reported increased numbers of MCs in the gingiva of patients
with periodontal disease compared with controls and a significant correlation
between MC density, degree of degranulation and periodontitis severity has been
reported (132). Expression of LL-37 is increased in gingival crevicular fluid of
patients with periodontitis and a significantly higher basal hBD3 expression in
keratinocytes from periodontitis patients compared to controls has been reported
(135, 136). Our finding that MrgX2 is expressed in healthy and diseased gingival
MCs, suggests that gingival MrgX2-positive MCs contribute to host defense in
the oral cavity via activation by AMPs. It is also possible that MrgX2 also
contributes to CP due elevated hBD3/LL-37 and increased number of MrgX2expressing MCs.
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We demonstrated that MCs in healthy and asthmatic lung express MrgX2. The
number of MCs, MrgX2-positive cells as well as MrgX2-positive MCs were
significantly increased in lung tissue from individuals who died from asthma
patients compared to individuals who died from other causes. Also, an increased
number of MCs were present in the lung smooth muscle of asthma patients
compared with controls. This finding is consistent with previous reports that the
number of MCTC is increased in bronchial smooth muscles of patients with
asthma compared with controls (144, 146). It is noteworthy that MCTC express
GPCRs for MrgX2 (147). Eosinophils and neutrophils play important roles in the
last phase of asthma (153). Eosinophil-derived MBP as well as neutrophilderived LL-37 activate MCs via MrgX2 (63, 65). In children, asthma is
exacerbated by HRV and RSV, which are both associated with increased
induction of hBDs in bronchial epithelial cells (148). Therefore it appears that
MCTC, which are recruited to the lungs of asthmatics, are activated by hBDs, LL37 and MBP via MrgX2 leading to release of mediators, which cause
bronchospasm and exacerbates the asthma symptoms.

Unlike most GPCRs that are expressed on MCs, MrgX2 is located at both
plasma membrane and intracellular sites (65, 162). Using RBL-2H3 cells
transiently transfected with HA-tagged MrgX2, we also obtained similar results,
which indicate that MrgX2 ligands can activate MCs via interaction with the
receptor at the plasma membrane and intracellular sites. Prior studies have
shown that MrgX2 is resistant to agonist-induced receptor phosphorylation,
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desensitization and internalization (63). Although MrgX2 remained on the plasma
membrane and intracellularly on stimulation with CST in this study, there was a
more punctate and peri-nuclear appearance indicating that there may be some
mobilization of the receptor. More studies are ongoing to identify the exact
intracellular location of the receptor before and after stimulation.

MrgX2 is expressed in human but not in mouse MCs, thus making it difficult to
target the receptor for in vivo studies. Humanized mice have recently been used
to study the role of human MCs in vivo. However, the possibility that these MCs
express MrgX2 has not been previously tested. We found that as for asthmatic
human lung MCs, lung of humanized mice develop human MCs that express
MrgX2. Preliminary studies performed by others in Dr. Ali’s lab have shown that
human MCs develop in the skin and gingiva of humanized mice.

Therefore,

humanized mice may be used as models to study the role of MrgX2 on host
defense and chronic inflammatory diseases such as AD, rosacea, periodontitis
and asthma.

6. CONCLUSIONS
MCs have various functions in both health and disease. Prior studies have shown
that a wide range of structurally unrelated small cationic peptides including AMPs
and neuropeptides induce dose-dependent degranulation of MCs via MrgX2 (32,
63, 64). This study has shown that MrgX2 is expressed in healthy human skin,
gingiva and lung tissue. This suggests that activation of MrgX2 on MCs by AMPs
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generated by the epithelium (hBDs) and neutrophil (LL-37) plays a pivotal role in
host defense. Currently, around 500 - 600 AMPs are in clinical development for
the treatment of microbial infection; the mechanisms of their action include both
antimicrobial activity and the modulation of the immune system (168). However,
a major limitation of this strategy is that chemical synthesis of these AMPs is
prohibitively expensive and post-synthesis modifications (cyclization, disulfide
bonds, folding) are inadequate for optimal antimicrobial activity. Gupta et al.,
recently demonstrated that AMPs such as retrocyclin and protegrin purified from
transgenic plant chloroplasts kill microbes directly and induce MC degranulation
via MrgX2 (162). Thus, harnessing this dual feature of plant generated AMPs
could facilitate their advancement to the clinic for the treatment of periodontal
and cutaneous microbial infection overcoming major hurdles in current
production systems.

This study has demonstrated the presence of MrgX2-positive MCs in the skin of
patients with AD and rosacea as well as gingiva tissue from CP patients. Given
that eosinophil-derived peptides, LL-37 and hBDs are increased in AD, rosacea
and CP respectively suggest that MrgX2 contributes to these diseases via
increased MC degranulation. Our finding that MCs that express MrgX2 are
upregulated in chronic asthma suggests it participates in the pathogenesis of
asthma and may be potentially targeted for its treatment. Finally, we found that
human MCs, which develop in the lungs of humanized mice, express MrgX2.
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Therefore humanized mice may be used as models for future in vivo studies on
the role of MrgX2 on host defense and chronic inflammatory diseases.
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8. FIGURE LEGEND
Figure 1. MCs in skin of patients with AD. IHC was performed on human skin
tissue from (A and B) control subjects and (C and D) patients diagnosed with AD
using the MC marker tryptase. Note dark brown cytoplasmic staining of MCs.
Most MCs were observed in the dermal layers in both healthy and diseased skin
tissue compared to the epidermis. 4X scale bar = 2 mm while 20X scale bar =
200 μm.

Figure 2. MrgX2 is expressed in skin MCs of normal subjects and patients
with AD. IF was performed on human skin tissue from

(A and B) control

subjects and (C and D) AD patients. MrgX2 is shown in red, tryptase in green
and the nuclei blue. Note that there is a greater degree of colocalization in AD
compared with normal. Images taken at 40X magnification using a Nikon Eclipse
fluorescent microscope. Scale bar = 50μm.

Figure 3. MC number in normal and AD skin. Skin samples from 3 patients
diagnosed with AD and 3 control patients were analyzed using IF. Pictures were
taken from 5 randomly selected visual fields in each skin sample at a
magnification of 40X. Image exposure, size and dimensions were exactly the
same for all analyzed images. The number of skin MCs was not significantly
different in skin of AD patients compared with control subjects.
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Figure 4. Intensity of MrgX2 expression by MCs in AD. Using colocalized IF
images, the intensity of the green tryptase staining by MCs as well as red MrgX2
staining in the same MCs was measured using Metamorph image analysis
software. Image exposure was exactly the same for all analyzed images. The
intensity of tryptase expression by MCs was not significantly different in skin
tissues from control subjects compared with AD patients. There was also no
significant difference in the intensity of MrgX2 expression by MCs between the 2
groups.

Figure 5. MCs in skin of patients with rosacea. IHC was performed on human
skin tissue from (A and B) control subjects and (C and D) patients diagnosed with
rosacea using the MC marker tryptase. Note dark brown cytoplasmic staining of
MCs. Most MCs were observed in the dermal layers in both healthy and diseased
skin tissue compared to the epidermis. 4X scale bar = 2 mm while 20X scale bar
= 200 μm.

Figure 6. MrgX2 is expressed in skin MCs of normal subjects and patients
with rosacea. IF was performed on human skin tissue from (A and B) control
subjects and (C and D) rosacea patients. MrgX2 is shown in red, tryptase in
green and the nuclei blue. Note that there is a greater degree of colocalization in
rosacea compared with normal. Images taken at 40X magnification using a Nikon
Eclipse fluorescent microscope. Scale bar = 50μm.
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Figure 7. MC number in normal and rosacea skin. Skin samples from 2
patients diagnosed with rosacea and 3 control patients were analyzed using IF.
Pictures were taken from 5 randomly selected visual fields in each skin sample at
a magnification of 40X. Image exposure, size and dimensions were exactly the
same for all analyzed images. The number of skin MCs was not significantly
different in skin of rosacea patients compared with control subjects.

Figure 8. Intensity of MrgX2 expression by MCs in rosacea. Using
colocalized IF images, the intensity of the green tryptase staining by MCs as well
as red MrgX2 staining in the same MCs was measured using Metamorph image
analysis software. Image exposure was exactly the same for all analyzed
images. The intensity of tryptase expression by MCs was significantly reduced in
skin tissues from rosacea patients compared with control (P = 0.0260). However,
there was no significant difference in the intensity of MrgX2 expression by MCs
between the 2 groups.

Figure 9. MCs in gingiva of patients with CP. IHC was performed on human
gingiva tissue from (A and B) control subjects and (C and D) patients diagnosed
with CP using the MC marker tryptase. Note dark brown cytoplasmic staining of
MCs. Most of the MCs are present in the lamina propria and submucosa in both
healthy and diseased gingiva tissue compared to the epithelium. Also note that
gingiva samples from patients with CP have a greater number of MCs in the

78

epithelium compared to the healthy gingiva. 4X scale bar = 2 mm while 20X scale
bar = 200 μm

Figure 10. MrgX2 is expressed in gingival MCs of normal subjects and
patients with CP. IF was performed on human gingiva tissue from (A and B)
control subjects and (C and D) CP patients. MrgX2 is shown in red, tryptase in
green and the nuclei blue. Note that there is a greater degree of colocalization in
CP gingiva compared with normal gingiva. Images taken at 40X magnification
using a Nikon Eclipse fluorescent microscope. Scale bar = 50μm.

Figure 11. MCs in lung of patients with asthma. IHC was performed on human
lung tissue from (A and B) control subjects who died from non-asthma related
causes and (C and D) patients who died from asthma complications using the
MC marker tryptase. Note dark brown cytoplasmic staining of MCs. An increased
number of MCs are present in the lung smooth muscles of asthma patients
compared to healthy lung. 10X scale bar = 500 μm while 20X scale bar = 200 μm

Figure 12. MrgX2 is expressed in lung MCs of normal subjects and patients
with asthma. IF was performed on human lung tissue from (A and B) control
subjects who died from non-asthma related causes and (C and D) asthma
patients who died from asthma complications. MrgX2 is shown in red, tryptase in
green and the nuclei blue. Note that there is a greater degree of colocalization in
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asthma lung compared with normal lung. Images taken at 40X magnification
using a Nikon Eclipse fluorescent microscope. Scale bar = 50μm.

Figure 13. MC number in normal and asthma lung. Lung tissue from 6
patients who died from asthma-related complications and 6 control patients who
died from non-asthma related causes were analyzed using IF. Pictures were
taken from 3 randomly selected visual fields in each sample at a magnification of
20X. Image exposure, size and dimensions were exactly the same for all
analyzed images. The number of lung MCs was significantly greater in lung
tissue from patients who died from asthma complications compared with control
subjects (P= 0.0178). The number of MrgX2-positive cells was also significantly
greater in lung tissue from patients who died from asthma complications
compared with control subjects (P= 0.0211). In both healthy and asthmatic lungs,
a proportion of MrgX2-positive cells were not MCs.

Figure 14. Number of MrgX2-positive MCs in normal and asthma lung.
Image analysis was performed as in Fig. 13. The number of MrgX2-positive MCs
was significantly greater in lung tissue from patients who died from asthma
complications compared with control subjects (P=0.0176).

Figure 15. MrgX2 localization in RBL-2H3 cells transiently expressing HAtagged MrgX2. IF analysis was performed on RBL-2H3 cells transiently
expressing HA- tagged MrgX2 before and after stimulation with CST using anti-
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HA antibody for the detection of MrgX2. Prior to stimulation with CST, MrgX2 is
diffusely expressed on the plasma membrane as well as the cytoplasm. On
stimulation with CST, the receptor remained on the plasma membrane as well as
in the cytoplasm but with a more peri-nuclear and punctate appearance. Images
taken at 20X magnification using a Nikon Eclipse fluorescent microscope. Scale
bar = 100μm.

Figure 16. Effects of LL-37 and SP-induced degranulation on RBL-2H3 cells
stably expressing MrgX2. RBL-2H3 cells stably expressing MrgX2 were
exposed to buffer (control), LL-37 at 5μM and 10μM and SP at 5μM and 10μM.
Percentage degranulation (β-hexosaminidase release) was determined. Data are
Mean ± SEM of 3 experiments.

Figure 17. Human MCs in the lung of NSG-SGM3 mice preconditioned with
busulfan express MrgX2. IHC performed with tryptase antibody demonstrates
that human MCs develop in the lung of humanized mice preconditioned with
busulfan (Fig. 17A). IF was also performed on the humanized mice lung tissue
(Fig. 17B). MrgX2 is shown in red, tryptase in green and the nuclei blue. Images
taken at 40X magnification using a Nikon Eclipse fluorescent microscope. Scale
bar = 50μm.

Figure 18. Human MCs in the lung of NSG-SGM3 mice preconditioned by
irradiation express MrgX2. IHC performed with tryptase antibody demonstrates
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that human MCs develop in the lung of humanized mice preconditioned by
irradiation (Fig. 18A). IF was also performed on the humanized mice lung tissue
(Fig. 18B). MrgX2 is shown in red, tryptase in green and the nuclei blue. Images
taken at 40X magnification using a Nikon Eclipse fluorescent microscope. Scale
bar = 50μm.
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